Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

KALETRA

LOPINAVIR; RITONAVIR

Standard Dose
133.3MG;33.3MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview KALETRA is listed in Drugs@FDA under application 021226 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LOPINAVIR; RITONAVIR Form and strength CAPSULE;ORAL - 133.3MG;33.3MG Sponsor ABBVIE Submission history Latest submission status date: 2020-10-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview KALETRA is listed in Drugs@FDA under application 021226 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LOPINAVIR; RITONAVIR Form and strength CAPSULE;ORAL - 133.3MG;33.3MG Sponsor ABBVIE Submission history Latest submission status date: 2020-10-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
KALETRA (LOPINAVIR; RITONAVIR) | Drug Monograph | MedicHelpline